Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro

Konstantin A. Krychtiuk(Ludwig Boltzmann Institute for Cardiovascular Research), Walter S. Speidl(University of Applied Sciences St Pölten), Johann Wojta(Medical University of Vienna), Andreas Zuckermann(Medical University of Vienna), Philipp J. Hohensinner(Ludwig Boltzmann Institute for Age Research), Stefan Kastl(Medical University of Vienna), Sabine Rauscher(Medical University of Vienna), Wolfgang Eppel(Medical University of Vienna), Gerald Maurer(European Society of Radiology), Kurt Huber(Sigmund Freud Privatuniversität Wien), Rainer de Martin(Deaconess Hospital), Jacqueline Seigner(Medical University of Vienna), Christoph Kaun(University of Vienna), Stefan Stojković
Vascular Pharmacology
February 10, 2017
10.1016/j.vph.2017.02.003
Cited by 16

Related Papers

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
|The Lancet|2018|793
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755